Compare Monster Beverage Corp (MNST) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs BIO-TECHNE Corp — how do they compare? Monster Beverage Corp trades at $42.92 (market cap $84.53B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Monster Beverage Corp is far larger — about 7.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | TECH | |
|---|---|---|
Market Cap | $84.53B | $11.34B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $72.48 |
52-Week Low | $31.41 | $43.31 |
Enterprise Value | $82.83B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed August 11, 2026. The stock shows strong fundamental performance with revenue growing from $6.3B in 2022 to $8.3B in 2025, while net income expanded to $1.91B. Technical indicators present a mixed picture with bullish oscillators but bearish moving averages, creating uncertainty in the near-term direction. Analyst consensus remains positive with 51% buy ratings and a $51.10 price target representing 18% upside potential.
MNST offers compelling growth prospects driven by 20%+ revenue growth and expanding international presence (46% of Q2 2026 sales). However, elevated valuation multiples (P/E 39.95, P/S 9.24) and rising cost pressures present risks. The company's consistent earnings beats and strong cash flow generation support the bullish case, but investors should weigh growth potential against premium valuation in a competitive beverage market.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
